© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Absci Corporation (ABSI) stock declined over -3.68%, trading at $10.21 on NASDAQ, down from the previous close of $10.60. The stock opened at $10.34, fluctuating between $10.10 and $10.62 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 13, 2026 | 10.34 | 10.61 | 10.10 | 10.21 | 2.92M |
| Jul 10, 2026 | 11.37 | 11.41 | 10.32 | 10.60 | 4.69M |
| Jul 09, 2026 | 11.18 | 12.00 | 10.90 | 11.47 | 4.96M |
| Jul 08, 2026 | 10.96 | 11.14 | 10.41 | 11.10 | 6.59M |
| Jul 07, 2026 | 11.85 | 12.00 | 11.11 | 11.33 | 4.14M |
| Jul 06, 2026 | 11.63 | 12.00 | 11.33 | 11.54 | 5.47M |
| Jul 02, 2026 | 11.40 | 11.78 | 11.14 | 11.62 | 5.26M |
| Jul 01, 2026 | 11.12 | 11.69 | 10.83 | 11.11 | 5.08M |
| Jun 30, 2026 | 11.34 | 11.78 | 10.99 | 11.59 | 5.81M |
| Jun 29, 2026 | 10.98 | 12.06 | 10.96 | 11.35 | 8.1M |
| Jun 26, 2026 | 10.02 | 11.36 | 9.96 | 10.89 | 13.43M |
| Jun 25, 2026 | 11.00 | 11.25 | 9.32 | 10.21 | 13.21M |
| Jun 24, 2026 | 9.51 | 11.00 | 8.67 | 10.07 | 38.16M |
| Jun 23, 2026 | 7.92 | 8.29 | 7.37 | 7.41 | 5.98M |
| Jun 22, 2026 | 7.51 | 8.57 | 7.47 | 8.40 | 8.35M |
| Jun 18, 2026 | 7.46 | 7.55 | 7.11 | 7.41 | 8.44M |
| Jun 17, 2026 | 7.00 | 7.84 | 6.92 | 7.18 | 6.34M |
| Jun 16, 2026 | 7.29 | 7.38 | 6.83 | 7.00 | 3.83M |
| Jun 15, 2026 | 7.38 | 8.17 | 7.13 | 7.27 | 6.68M |
| Jun 12, 2026 | 6.60 | 7.09 | 6.36 | 6.80 | 4.46M |
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
| Employees | 156 |
| Beta | 2.33 |
| Sales or Revenue | $5.72M |
| 5Y Sales Change% | 1.782% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |